share_log

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results

Hims & Hers Health | 8-K：Hims & Hers Health, Inc. 公佈2024年第三季度財務業績
美股SEC公告 ·  2024/11/05 05:14

Moomoo AI 已提取核心訊息

Hims & Hers Health reported strong Q3 2024 results with revenue reaching $401.6 million, up 77% YoY, driven by robust growth across both Hims and Hers brands. The company achieved net income of $75.6 million, including a $60.8 million tax benefit, compared to a $7.6 million loss in Q3 2023. Adjusted EBITDA was $51.1 million, up from $12.3 million last year.The company's subscriber base grew 44% YoY to 2 million, with monthly revenue per average subscriber increasing 24% to $67. Gross margin was 79%, while net cash from operations reached $85.3 million. The new weight loss offering has become a growth accelerator, with core subscriber growth excluding GLP-1 solutions up 40% YoY.Based on strong performance, Hims & Hers raised its full-year 2024 guidance, now expecting revenue of $1.46-1.47 billion and Adjusted EBITDA of $173-178 million. For Q4 2024, the company projects revenue of $465-470 million and Adjusted EBITDA of $50-55 million.
Hims & Hers Health reported strong Q3 2024 results with revenue reaching $401.6 million, up 77% YoY, driven by robust growth across both Hims and Hers brands. The company achieved net income of $75.6 million, including a $60.8 million tax benefit, compared to a $7.6 million loss in Q3 2023. Adjusted EBITDA was $51.1 million, up from $12.3 million last year.The company's subscriber base grew 44% YoY to 2 million, with monthly revenue per average subscriber increasing 24% to $67. Gross margin was 79%, while net cash from operations reached $85.3 million. The new weight loss offering has become a growth accelerator, with core subscriber growth excluding GLP-1 solutions up 40% YoY.Based on strong performance, Hims & Hers raised its full-year 2024 guidance, now expecting revenue of $1.46-1.47 billion and Adjusted EBITDA of $173-178 million. For Q4 2024, the company projects revenue of $465-470 million and Adjusted EBITDA of $50-55 million.
Hims & HERS Health公佈了強勁的2024年第三季度業績，營業收入達到40160萬，較去年同期增長77%，主要得益於Hims和HERS品牌的強勁增長。公司實現了7560萬的凈利潤，其中包括6080萬的稅收優惠，而2023年第三季度則錄得760萬的虧損。調整後的EBITDA爲5110萬，較去年的1230萬大幅上升。公司的訂閱用戶數量同比增長44%，達到200萬，平均每位用戶的月收入增長24%，達到67美元。毛利率爲79%，運營產生的淨現金達到8530萬。新的減重產品已經成爲增長加速器，核心訂閱用戶增長（不包括GLP-1解決方案）同比增長40%。基於強勁的表現，Hims & HERS上調了2024年全年的指導預期，現在預計營業收入爲146-147億，調整後的EBITDA爲17300-17800萬。對於2024年第四季度，公司預計營業收入爲46500-47000萬，調整後的EBITDA爲5000-5500萬。
Hims & HERS Health公佈了強勁的2024年第三季度業績，營業收入達到40160萬，較去年同期增長77%，主要得益於Hims和HERS品牌的強勁增長。公司實現了7560萬的凈利潤，其中包括6080萬的稅收優惠，而2023年第三季度則錄得760萬的虧損。調整後的EBITDA爲5110萬，較去年的1230萬大幅上升。公司的訂閱用戶數量同比增長44%，達到200萬，平均每位用戶的月收入增長24%，達到67美元。毛利率爲79%，運營產生的淨現金達到8530萬。新的減重產品已經成爲增長加速器，核心訂閱用戶增長（不包括GLP-1解決方案）同比增長40%。基於強勁的表現，Hims & HERS上調了2024年全年的指導預期，現在預計營業收入爲146-147億，調整後的EBITDA爲17300-17800萬。對於2024年第四季度，公司預計營業收入爲46500-47000萬，調整後的EBITDA爲5000-5500萬。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間